ADCytherix

adcytherix.com

adcytherix.com • Likely startup • New

Likely startup • New

Actively hiring

Biotechnology

Overview

Salaries

Products

People

Growth

Offices

Financials

Funding and backers

Backers

RA Capital Management, aMoon

Momentum

0/100

no fresh signals

Backed byfrom the funds' portfolios and accelerator catalogs

RA Capital Management fund

aMoon fund

Angelini Ventures fund

Kurma Partners fund

Pontifax fund

Similar startupsby what they do, their industry and backers

Araris Biotech

Building tomorrow's antibody-drug conjugates (ADCs). Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH…

Alentis TherapeuticsFounded 2019 • 51-200 employees

THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…

Ona TherapeuticsFounded 2019 • 51-200 employees

First-in-class ADCs tailored to attack advanced cancer.. Ona Therapeutics is pioneering the development of first-in-class antibody drug…

Hexagon BioSeries B $77.3M · 3 yr ago • Founded 2016 • 201-500 employees • 1 role

Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance…

Lassogen, Inc.Venture round $5.1M · 6 yr ago • Founded 2019 • 11-50 employees

Lassogen is developing a new therapeutic modality based on lasso peptides that we are programming to treat difficult diseases such as…

AngiexVenture round $22M · 13 mo ago • Founded 2015 • 201-500 employees

Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.

Overview

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. The company was founded by the previous founders of Emergence Therapeutics.